Parallax Volatility Advisers
BEAM icon

Parallax Volatility Advisers’s Beam Therapeutics BEAM Stock Holding History

Parallax Volatility Advisers’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-100
Closed -$13K – 3001
2021
Q2 		$13K Buy
+100
New +$7.97K ﹤0.01% 2754

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Parallax Volatility Advisers's BEAM Position: Q2 2025 in Review

Parallax Volatility Advisers sold out of Beam Therapeutics (BEAM) in Q2 2025, closing a stake of 3,259 shares — an estimated $63.6K sold.

Parallax Volatility Advisers first reported a position in BEAM in Q1 2021 and held it in 2 quarters. The position peaked at $63.6K in Q1 2025. 217 funds tracked by Wall St. Rank hold BEAM as of Q2 2025.

  • Parallax Volatility Advisers reported no remaining Beam Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Parallax Volatility Advisers sold 3,259 Beam Therapeutics shares in Q2 2025, an estimated $63.6K.
  • Parallax Volatility Advisers first reported a position in Beam Therapeutics in Q1 2021 and held it in 2 quarters.
  • Parallax Volatility Advisers's Beam Therapeutics position peaked at $63.6K in Q1 2025.
  • 217 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2025.

Based on Parallax Volatility Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.